search
Back to results

Improved Implant for Reconstruction Purposes After Mandibular Resection (RifRam)

Primary Purpose

Head and Neck Cancer, Oral Cancer

Status
Recruiting
Phase
Not Applicable
Locations
Netherlands
Study Type
Interventional
Intervention
RIFRAM implant
Sponsored by
The Netherlands Cancer Institute
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Head and Neck Cancer focused on measuring surgery, COMMANDO

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Age ≥ 18 years at time of study entry.
  • T4 oral cavity tumor with mandible invasion, requiring segmental mandibulectomy.
  • Reconstruction with free fibula flap not feasible because of any or a combination of the following reasons:

oCT angiography of the legs and/or the neck shows severe stenosis of the ves-sels.

  • Previous medical history of severe atherosclerotic disease.
  • General health condition necessitating a shorter operation time.

    • Cases will be discussed in the multidisciplinary tumor board that they are eligible for composite resection but not eligible for free fibula flap.
    • Written informed consent.

Exclusion Criteria:

  • Patients who are eligible for free fibula flap.
  • Pregnancy.
  • General health condition does not allow surgery
  • History of psychiatric disability judged by the investigator to potentially hamper compliance with the study protocol and follow-up schedule.
  • Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule.

Sites / Locations

  • Antoni van LeeuwenhoekRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

RIFRAM implant

Arm Description

RIFRAM implant

Outcomes

Primary Outcome Measures

Surgical fit
good fit during surgery, suboptimal fit of the mandible making placement not possible.
Complications
Implant related complications leading to implant loss

Secondary Outcome Measures

Full Information

First Posted
November 29, 2021
Last Updated
December 16, 2021
Sponsor
The Netherlands Cancer Institute
search

1. Study Identification

Unique Protocol Identification Number
NCT05153733
Brief Title
Improved Implant for Reconstruction Purposes After Mandibular Resection
Acronym
RifRam
Official Title
Improved Implant for Reconstruction Purposes After Mandibular Resection
Study Type
Interventional

2. Study Status

Record Verification Date
December 2021
Overall Recruitment Status
Recruiting
Study Start Date
November 29, 2021 (Actual)
Primary Completion Date
November 29, 2023 (Anticipated)
Study Completion Date
November 29, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
The Netherlands Cancer Institute

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Study design: A single center non-randomized, prospective clinical feasibility study. Study population: Study population is composed of 10 patients ineligible for a free-flap bone reconstruction. Intervention: The selected patients will receive the newly developed, patient-specific RIfRaM mandibular implant. Objective: The aim is to provide enough evidence through model analysis, physical tests and clinical study of 10 patients that our new type of personalized mandibular implant is safe to use, resulting in significantly fewer complications and can be practically placed during the surgery, without any complications. Main study parameters/endpoints: The study endpoint is to use the RifRaM without any implant related complications and a perfect mandibular fit.
Detailed Description
The preoperative bony resection planning and the design of the RifRam implant will be carried out on 3D reconstructed CT image of the mandible. The necessary resection planes will be marked on the 3D model. This segment will be removed virtually and replaced by the designed RifRam implant. The form of the implant will follow the contours of the native healthy mandible. In case, extensive bone destruction of the mandible does not allow copying the contours, contralateral side of the mandible will be virtually mirrored and used to design the implant. The design of the implant will be carried out within the NKI/AVL and the data will be preserved in restricted access folders. The designed implant will be printed with a hollow mesh core by Mobius. A matching cutting guide will be printed as well. Two copies of the implant will be delivered in case one would be accidentally be unsterile (see 5.3). The cutting guides are used to cut the mandible at exactly the intended places. The implant and the cutting guide will be delivered to the hospital and sterilized by Clinium for clinical use. The patient will undergo a COMMANDO (combined mandibulectomy and neck dissection) procedure. The steps of this procedure are well defined and can be found in iProva. The oncological resection will be carried out in the standard fashion. Mandible saw cutting guides are used as standard procedure. The patient specific mandible cutting guide will be fixed on the mandible and the cuts to the mandible will be made through the cutting slots. This step enables that the mandible defect matches exactly the RifRam implant. After the resection is completed and the surgical site irrigated as per standard procedure, the Rifram implant will be placed to fill the bone defect. The implant will be fixed with 2.7 mm locking screws produced by KLS Martin. These screws are used are used as standard and are available in stock in the operation complex. The soft tissue defect will be reconstructed using a regional flap such as pectoralis major musculocutaneous flap. The rest of the procedure will be completed as per established clinical protocol.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Head and Neck Cancer, Oral Cancer
Keywords
surgery, COMMANDO

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
10 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
RIFRAM implant
Arm Type
Experimental
Arm Description
RIFRAM implant
Intervention Type
Device
Intervention Name(s)
RIFRAM implant
Other Intervention Name(s)
COMMANDO
Intervention Description
Participants will receive the newly developed, patient-specific RIfRaM mandibular implant.
Primary Outcome Measure Information:
Title
Surgical fit
Description
good fit during surgery, suboptimal fit of the mandible making placement not possible.
Time Frame
intra-operative
Title
Complications
Description
Implant related complications leading to implant loss
Time Frame
implant loss in 1-year post-operational follow-up.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Age ≥ 18 years at time of study entry. T4 oral cavity tumor with mandible invasion, requiring segmental mandibulectomy. Reconstruction with free fibula flap not feasible because of any or a combination of the following reasons: oCT angiography of the legs and/or the neck shows severe stenosis of the ves-sels. Previous medical history of severe atherosclerotic disease. General health condition necessitating a shorter operation time. Cases will be discussed in the multidisciplinary tumor board that they are eligible for composite resection but not eligible for free fibula flap. Written informed consent. Exclusion Criteria: Patients who are eligible for free fibula flap. Pregnancy. General health condition does not allow surgery History of psychiatric disability judged by the investigator to potentially hamper compliance with the study protocol and follow-up schedule. Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Robert van Veen, PhD
Phone
+31205122550
Email
r.v.veen@nki.nl
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Baris Karakullukcu, PhD
Organizational Affiliation
The Netherlands Cancer Institute
Official's Role
Principal Investigator
Facility Information:
Facility Name
Antoni van Leeuwenhoek
City
Amsterdam
State/Province
NH
ZIP/Postal Code
1082 MK
Country
Netherlands
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Baris Karakullukcu, PhD
Phone
+31205122550
Email
b.karakullukcu@nki.nl
First Name & Middle Initial & Last Name & Degree
Klaske van Sluis, PhD
Phone
+31205122550
Email
k.v.sluis@nki.nl

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Improved Implant for Reconstruction Purposes After Mandibular Resection

We'll reach out to this number within 24 hrs